Pharma research firm APC partners to develop Covid-19 vaccine with Vaxine
Irish company working with Australian vaccine developer Vaxine on a new candidate
Irish pharmaceutical research company APC has partnered with an Australian biotech firm to accelerate the development and launch of a vaccine for coronavirus.
The pharmaceutical research company, which designs, develops, and markets proprietary engineering platform technologies that reduce the time, cost, and risk in the development of medicines, is teaming up with Vaxine Pty, an Adelaide-headquartered vaccine developer which spun out of the National Health Sciences Centre in Canberra.
Vaxine has developed a broad range of candidates that use its proprietary Advax technology including vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, and rabies.
The Australian company has partnered with several companies recently to progress its novel Covax-19 vaccine, which uses Advax combined with a recombinant Sars-CoV-2 spike protein. The vaccine is in its last phase of non-clinical animal testing, with clinical trials planned for the fourth quarter and a product launch set for early 2021.
Full Link to the article: